劉文婧                                                    

學(xué)歷：醫(yī)學(xué)博士

職稱：助理研究員

郵箱：[email protected]

通訊地址：云南省昆明市呈貢區(qū)雨花街道春融西路1168號(hào)

郵編：650500

簡(jiǎn)歷

2010.09-2014.06, 魯東大學(xué)，生命科學(xué)學(xué)院,，生物科學(xué),，理學(xué)學(xué)士  

2014.09-2017.06, 昆明理工大學(xué)，醫(yī)學(xué)院,，細(xì)胞生物學(xué),，理學(xué)碩士  

2017.09-2022.06, 中國(guó)科學(xué)院大學(xué)，基礎(chǔ)醫(yī)學(xué)（病理學(xué)與病理生理學(xué)）,，醫(yī)學(xué)博士  

2022.08-2024.08, 昆明醫(yī)科大學(xué)第三附屬醫(yī)院,，臨床醫(yī)學(xué)，博士后  

2025.03-至今, 昆明醫(yī)科大學(xué),，生物醫(yī)學(xué)工程研究院, 助理研究員

研究方向

主要集中在蛋白質(zhì)翻譯后修飾和DNA損傷應(yīng)答與腫瘤放化療抵抗,。腫瘤對(duì)放化療的耐受性是腫瘤學(xué)研究中的核心問題，也是現(xiàn)代腫瘤生物學(xué)研究的重要方向,。過度激活的DNA損傷應(yīng)答是導(dǎo)致腫瘤細(xì)胞對(duì)放射化療抵抗的關(guān)鍵分子機(jī)制之一,。解析DNA損傷應(yīng)答的動(dòng)態(tài)平衡失調(diào)的分子機(jī)制，是理解腫瘤發(fā)生放化療耐受的基礎(chǔ),。同時(shí),，DNA損傷應(yīng)答信號(hào)的傳導(dǎo)主要依賴于蛋白質(zhì)的翻譯后修飾，如磷酸化,、泛素化和乳酸化等相關(guān)的可逆修飾,，以實(shí)現(xiàn)DNA損傷蛋白質(zhì)的有序連接。圍繞DNA損傷修復(fù)應(yīng)答失調(diào)介導(dǎo)的腫瘤放化療抵抗這一核心科學(xué)問題,，深入研究蛋白質(zhì)的翻譯后修飾介導(dǎo)的DNA損傷應(yīng)答分子調(diào)控網(wǎng)絡(luò)在腫瘤抵抗放化療中的作用機(jī)制,，發(fā)現(xiàn)新的腫瘤治療靶點(diǎn)。并基于已識(shí)別的靶點(diǎn)篩選小分子化合物或小肽,，以期為腫瘤的放化療耐受提供新的治療手段,。

承擔(dān)科研項(xiàng)目

1.國(guó)家自然科學(xué)基金委員會(huì)，國(guó)家自然科學(xué)基金青年基金項(xiàng)目,，82403795,， BRCC3通過穩(wěn)定EGR1增強(qiáng)乳腺癌放療抵抗的功能和機(jī)制研究，2025.01至2027.12,，30萬元,，在研，主持。

2.中國(guó)博士后科學(xué)基金會(huì),，中國(guó)博士后科學(xué)基金面上項(xiàng)目,，2023M731448， RNF126對(duì)睪丸精子發(fā)生的分子機(jī)制研究 ,，2023.06至2025.05,，8萬元，結(jié)題,，主持,。

3.科技創(chuàng)新2030—“癌癥、心腦血管,、呼吸和代謝性疾病防治研究”重大專項(xiàng),，2023ZD0502201，2024.08至2028.07,，4000萬元,，在研，參與（骨干成員）,。

4.國(guó)家自然科學(xué)基金委員會(huì),，國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目，82430084,， E3泛素連接酶BCA2調(diào)控乳腺發(fā)育和促乳腺癌進(jìn)展的功能和機(jī)制研究及靶向策略探索,， 2025.01至2029.12，230萬元,，在研,，參與。

研究成果（論文,、專利,、專著等）

主要論文

1. Wenjing Liu; Min Zheng; Rou Zhang; Qiuyun Jiang; Guangshi Du; Yingying Wu; Chuanyu Yang; Fubing Li; Wei Li; Luzhen Wang; Jiao Wu; Lei Shi; Wenhui Li; Kai Zhang; Zhongmei Zhou; Rong Liu; Yingzheng Gao; Xinwei Huang; Songqing Fan; Xu Zhi; Dewei Jiang; Ceshi Chen ; RNF126‐Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple‐Negative Breast Cancer to Radiotherapy; Advanced Science; 2023; 10(5): 2203884 (IF=14.1)

2. Wenjing Liu#; Xiya Sun#; Fubing Li#; Qiuyun Jiang; Jianting An; Yingying Wu; Jingyi Yang; Meng Qin; Yuxin Zhao; Yongjia Tang; Tingyue Wu; Zhiqiang Yan; Dewei Jiang; Rong Liu; Wenhui Li*; Xu Zhi*; Ceshi Chen*; An essential role of the E3 ubiquitin ligase RNF126 in ensuring meiosis I completion during spermatogenesis; Journal of Advanced Research; 2024 (IF=11.4)

3. Hongyan Zhang; Longlong Zhang; Yuna He; Dewei Jiang; Jian Sun; Qianmei Luo; Huichun Liang; Tiantian Wang; Fubing Li; Yu Tang; Zimo Yang;Wenjing Liu*; Yu Rao*; Ceshi Chen* PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer; Cancer Letters; 2024; 598:217112 (IF=9.1)

4. Min Zheng#;Wenjing Liu#; Rou Zhang; Dewei Jiang; Yujie Shi; Yingying Wu; Fei Ge*; Ceshi Chen*; E3 ubiquitin ligase BCA2 promotes breast cancer stemness by up-regulation of SOX9 by LPS; International Journal of Biological Sciences; 2024; 20(7), 2686-2697 (IF=8.3)

5. Maobo Huang#;Wenjing Liu#; Zhuo Cheng; Fubing Li; Yanjie Kong; Chuanyu Yang; Yu Tang; Dewei Jiang; Wenhui Li; Yudie Hu; Jinhui Hu*; Pematenzin Puno*; Ceshi Chen*; Targeting the HECTD3-p62 axis increases the radiosensitivity of triple negative breast cancer cells; Cell Death Discovery; 2024 (IF=6.1)

6.Hongyan Zhang#;Wenjing Liu#; Yingying Wu*; Ceshi Chen*; USP3: Key deubiquitylation enzyme in human diseases; Cancer Science; 2024 ;115(7), 2094-2106 (IF=5.5)

7.Tingyue Wu#;Wenjing Liu#; Hui Chen#; Lei Hou; Wenlong Ren; Longlong Zhang ; Jinhui Hu ; Haijun Chen; Ceshi Chen. Toxoflavin analog D43 exerts antiproliferative effects on breast cancer by inducing ROS-mediated apoptosis and DNA damage. Scientific Reports, 2024, 14(1): 4008  (IF=4.9)

8.Liu Wenjing#; Lu Xiaoqing#; Shi Peiguo#; Yang Guangxi; Zhou Zhongmei; Li Wei; Mao Xiaoyun; Jiang Dewei; Chen Ceshi ; TNF-alpha increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-kappa B pathway, Scientific Reports, 2020, 10(1):1804 (IF=4.9)

9.Jian Sun#;Wenjing Liu#; Yongbo Guo; Hailin Zhang; Dewei Jiang; Ying Luo; Rong Liu; Ceshi Chen ; Characterization of tree shrew telomeres and telomerase, Journal of Genetics and Genomics, 2021, 48(7): 631 (IF=5.751)

其他工作

1. Fubing Li; Huichun Liang; Hua You; Ji Xiao; Houjun Xia; Xi Chen; Maobo Huang; Zhuo Cheng; Chuanyu Yang;Wenjing Liu; Hailin Zhang; Li Zeng; Yingying Wu; Fei Ge; Zhen Li; Wenhui Zhou; Yi Wen; Zhongmei Zhou; Rong Liu; Dewei Jiang; Ni Xie; Bin Liang; Zhenzhen Liu; Yanjie Kong; Ceshi Chen; Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis; Signal Transduction and Targeted Therapy; 2022; 7: 264 (IF=38.1)

2. Jiao Wu; Sai-Ching Jim Yeung; Sicheng Liu; Aiham Qdaisat; Dewei Jiang; Wenli Liu; Zhuo Cheng;Wenjing Liu; Haixia Wang; Lu Li; Zhongmei Zhou; Rong Liu; Chuanyu Yang; Ceshi Chen; Runxiang Yang; Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS; Signal Transduction and Targeted Therapy; 2021; 6: 188 (IF=18.19)

3. Yaxun Guo#; Yuzhan Li#; Zhongmei Zhou#; Lei Hou;Wenjing Liu; Wenlong Ren; Dazhao Mi; Jian Sun; Xueqin Dai; Yingying Wu; Zhuo Cheng; Tingyue Wu; Qianmei Luo; Cong Tian; Fubing Li*; Zhigang Yu*; Yihua Chen*; Ceshi Chen*; Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer; Journal of Experimental & Clinical Cancer Research; 2024; 43: 314 (IF=11.2)

4. Wenlong Ren#; Huichun Liang#; Jian Sun; Zhuo Cheng;Wenjing Liu; Yingying Wu; Yujie Shi; Zhongmei Zhou; Ceshi Chen; TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis; Cell Death & Disease; 2024; 15: 821 (IF=9.0)

5. Luzhen Wang#; Dazhao Mi#; Jinhui Hu#;Wenjing Liu; Yi Zhang; Chunyan Wang; Yihua Chen; Ceshi Chen; A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer; Cancer Letters; 2023; 555: 216049 (IF=9.1)

6.Jia He#; Luzhen Wang#; Dazhao Mi; Tian Guan;Wenjing Liu; Peng He; Haijun Gu; Yuzhan Li; Yangrui Peng; Ai-Qun Jia; Ceshi Chen*; Yihua Chen*; Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer; Journal of Medicinal Chemistry; 2023; 66(11) (IF=6.3)

7. Yanjie Kong#; Tianlong Lan#; Luzhen Wang#; Chen Gong; Wenxin Lv; Hailin Zhang; Chengang Zhou; Xiuyun Sun;Wenjing Liu; Haihui Huang; Xin Weng; Chang Cai; Wenfeng Peng; Meng Zhang; Dewei Jiang; Chuanyu Yang; Xia Liu; Yu Rao; Ceshi Chen; BRD4-specific PROTAC inhibits basal-like breast cancer partially through downregulating KLF5 expression; Oncogene; 2024; 43: 2914–2926 (IF=9.9)

受邀為Cancer Lett、Int J Biol Sci,、Breast Cancer Research和npj Precision Oncology等期刊審稿人,。